Nothing Special   »   [go: up one dir, main page]

PT2723769T - Técnicas para prever, detetar e reduzir a interferência de proteínas não específicas em ensaios que envolvem domínios variáveis únicos de immunoglobulina - Google Patents

Técnicas para prever, detetar e reduzir a interferência de proteínas não específicas em ensaios que envolvem domínios variáveis únicos de immunoglobulina

Info

Publication number
PT2723769T
PT2723769T PT127299683T PT12729968T PT2723769T PT 2723769 T PT2723769 T PT 2723769T PT 127299683 T PT127299683 T PT 127299683T PT 12729968 T PT12729968 T PT 12729968T PT 2723769 T PT2723769 T PT 2723769T
Authority
PT
Portugal
Prior art keywords
predicting
techniques
detecting
variable domains
single variable
Prior art date
Application number
PT127299683T
Other languages
English (en)
Inventor
Snoeck Veerle
Baumeister Judith
Lucienne Armanda Bouche Marie-Paule
Boutton Carlo
Buyse Marie-Ange
Staelens Stephanie
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47423024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2723769(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/067132 external-priority patent/WO2012042026A1/en
Priority claimed from PCT/EP2012/061304 external-priority patent/WO2012175400A1/en
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of PT2723769T publication Critical patent/PT2723769T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PT127299683T 2011-06-23 2012-06-25 Técnicas para prever, detetar e reduzir a interferência de proteínas não específicas em ensaios que envolvem domínios variáveis únicos de immunoglobulina PT2723769T (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161500360P 2011-06-23 2011-06-23
US201161500464P 2011-06-23 2011-06-23
US201161541368P 2011-09-30 2011-09-30
PCT/EP2011/067132 WO2012042026A1 (en) 2010-09-30 2011-09-30 Biological materials related to c-met
US13/435,567 US8703135B2 (en) 2010-09-30 2012-03-30 Biological materials related to c-Met
PCT/EP2012/061304 WO2012175400A1 (en) 2011-06-23 2012-06-14 Serum albumin binding proteins

Publications (1)

Publication Number Publication Date
PT2723769T true PT2723769T (pt) 2017-04-04

Family

ID=47423024

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127299683T PT2723769T (pt) 2011-06-23 2012-06-25 Técnicas para prever, detetar e reduzir a interferência de proteínas não específicas em ensaios que envolvem domínios variáveis únicos de immunoglobulina

Country Status (22)

Country Link
US (11) US20180009888A9 (pt)
EP (1) EP2723769B2 (pt)
JP (6) JP6258199B2 (pt)
KR (7) KR102430693B1 (pt)
CN (5) CN108659120A (pt)
AU (7) AU2012273929B2 (pt)
BR (3) BR122017005075B1 (pt)
CA (3) CA3142288A1 (pt)
DK (1) DK2723769T4 (pt)
ES (1) ES2622006T5 (pt)
HU (1) HUE031828T2 (pt)
IL (4) IL293163A (pt)
IN (1) IN2014CN00373A (pt)
LT (1) LT2723769T (pt)
MX (2) MX350074B (pt)
PH (1) PH12017501178A1 (pt)
PL (1) PL2723769T5 (pt)
PT (1) PT2723769T (pt)
RU (1) RU2700630C2 (pt)
SG (4) SG10201707604SA (pt)
WO (1) WO2012175741A2 (pt)
ZA (1) ZA201309295B (pt)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434769B1 (en) 2009-10-30 2020-11-25 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
PE20130207A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2974737A1 (en) 2011-06-23 2016-01-20 Ablynx N.V. Techniques for predicting, detecting and reducing a specific protein interference in assays involving immunoglobulin single variable domains
LT2723771T (lt) 2011-06-23 2019-12-10 Ablynx Nv Serumo albuminą surišantys baltymai
SG10201707604SA (en) * 2011-06-23 2017-11-29 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2987806A3 (en) * 2011-08-17 2016-07-13 Glaxo Group Limited Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
AR088633A1 (es) 2011-11-04 2014-06-25 Novartis Ag Constructos extensores de vida media de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6)
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CN104781277A (zh) * 2012-09-13 2015-07-15 诺华股份有限公司 具有末端修饰的抗原结合分子
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
KR20170002645A (ko) * 2014-05-16 2017-01-06 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
WO2015173342A1 (en) 2014-05-16 2015-11-19 Ablynx Nv Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US10526397B2 (en) * 2015-01-21 2020-01-07 Inhibrx, Inc. Non-immunogenic single domain antibodies
ES2913200T3 (es) 2015-03-31 2022-06-01 Sorriso Pharmaceuticals Inc Polipéptidos
CA2981398A1 (en) 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd4 polypeptides with potent anti-hiv activity
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
DK3294768T3 (da) 2015-05-13 2019-11-11 Ablynx Nv T-celle-rekrutterende polypeptider baseret på tcr-alfa/beta-reaktivitet
LT3294319T (lt) 2015-05-13 2024-08-12 Ablynx Nv T ląsteles sutelkiantys polipeptidai pagal cd3 reaktyvumą
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
BR112018008754A2 (pt) 2015-10-30 2018-10-30 Ablynx Nv polipeptídeo contra il-23
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
NO2768984T3 (pt) 2015-11-12 2018-06-09
WO2017081265A1 (en) * 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
US11142569B2 (en) * 2015-11-13 2021-10-12 Ablynx N.V. Serum albumin-binding immunoglobulin variable domains
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
TW202216787A (zh) 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及／或 lag3結合劑
AU2016355568A1 (en) 2015-11-18 2018-06-21 Merck Sharp & Dohme Llc PD1/CTLA4 Binders
CN114605530A (zh) * 2015-11-18 2022-06-10 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
CA3006398A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
AU2016363787B2 (en) 2015-12-04 2023-02-02 Boehringer Ingelheim International Gmbh Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
MX2018016413A (es) * 2016-06-23 2019-05-09 Ablynx Nv Ensayos farmacocineticos mejorados para dominios variables unicos de inmunoglobulina.
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
KR20190127655A (ko) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. 음향학에 의한 친화성 세포 추출
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
KR102662499B1 (ko) 2017-01-17 2024-05-02 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
EP4442708A2 (en) * 2017-01-17 2024-10-09 Ablynx NV Improved serum albumin binders
AU2018241286A1 (en) 2017-03-31 2019-09-26 Ablynx N.V. Improved immunogenicity assays
AU2018276409A1 (en) 2017-05-31 2019-10-31 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
CA3064469A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
WO2018220234A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Adamts binding immunoglobulins
WO2018220236A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan
TW202413408A (zh) 2017-06-02 2024-04-01 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
KR102625929B1 (ko) 2017-07-19 2024-01-16 브이아이비 브이지더블유 혈청 알부민 결합제
JP6708797B2 (ja) 2017-08-23 2020-06-10 本田技研工業株式会社 鞍乗り型車両のエアバッグ装置
US11873347B2 (en) 2017-10-31 2024-01-16 Vib Vzw Antigen-binding chimeric proteins and methods and uses thereof
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EP3821255B1 (en) * 2018-07-10 2024-08-28 Regeneron Pharmaceuticals, Inc. Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
EP4065603A1 (en) 2019-11-27 2022-10-05 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
KR20220122652A (ko) 2019-12-06 2022-09-02 아블린쓰 엔.브이. TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
WO2021110817A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
WO2021116182A1 (en) 2019-12-09 2021-06-17 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
EP4110794A1 (en) 2020-02-25 2023-01-04 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP2023544124A (ja) 2020-09-25 2023-10-20 アブリンクス エン．ヴェー． Ｉｌ－１３およびｏｘ４０ｌを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022120388A2 (en) 2020-12-04 2022-06-09 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
BR112023011782A2 (pt) 2020-12-14 2023-10-31 Takeda Pharmaceuticals Co Proteínas de ligação condicionalmente biespecíficas
WO2022129560A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
US20240092919A1 (en) 2020-12-18 2024-03-21 Ablynx N. V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
KR20230141853A (ko) 2021-02-05 2023-10-10 브이아이비 브이지더블유 사베코바이러스 결합제
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
EP4294516A1 (en) 2021-02-19 2023-12-27 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
CN113173978B (zh) * 2021-04-22 2024-03-01 温州医科大学 一种对hpv16e6蛋白具有结合亲和力的多肽及其应用
EP4377352A2 (en) 2021-07-30 2024-06-05 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
WO2023093899A1 (zh) * 2021-11-29 2023-06-01 江苏恒瑞医药股份有限公司 经修饰的蛋白或多肽
EP4448783A1 (en) 2021-12-13 2024-10-23 Heraeus Medical GmbH Tests and methods for detecting bacterial infection
AU2022409733A1 (en) 2021-12-17 2024-08-01 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023164551A1 (en) 2022-02-23 2023-08-31 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
AR129560A1 (es) 2022-06-08 2024-09-04 Tidal Therapeutics Inc Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
AR129614A1 (es) 2022-06-14 2024-09-11 Ablynx Nv Dominios variables únicos de inmunoglobulina que se dirigen al receptor de células t
TW202423965A (zh) 2022-07-27 2024-06-16 比利時商艾伯霖克斯公司 與新生兒fc受體的特定表位結合之多肽
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate
WO2024137731A2 (en) 2022-12-21 2024-06-27 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US20240327538A1 (en) 2023-02-10 2024-10-03 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen and methods for making and using the same
US20240368250A1 (en) 2023-02-17 2024-11-07 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
ES2103770T3 (es) 1990-11-26 1997-10-01 Akzo Nobel Nv Procedimiento de produccion de anticuerpos monoclonales.
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2001002853A2 (en) 1999-07-05 2001-01-11 K.U. Leuven Research & Development DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
AU2001289930A1 (en) 2000-09-25 2002-04-08 Rega Stichting Vzw Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
US20040053340A1 (en) 2000-12-13 2004-03-18 De Haard Johannes Joseph Protein arrays
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CA2512545C (en) 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
AU2004205631A1 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20070087331A1 (en) 2003-05-15 2007-04-19 Cytos Biotechnology Ag Selection of b cells with specificity if interest: method of preparation and use
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US20070079391A1 (en) 2003-11-04 2007-04-05 Masayoshi Yamaguchi Hyperlipemia/hyperalbuminemia model animal
JP5068651B2 (ja) 2004-08-05 2012-11-07 ジェネンテック， インコーポレイテッド ヒト化抗ｃｍｅｔ抗体
WO2006059108A2 (en) 2004-12-02 2006-06-08 Domantis Limited ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
MX342271B (es) 2005-05-18 2016-09-21 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
JP4986997B2 (ja) 2005-05-20 2012-07-25 アブリンクス エン．ヴェー． 凝集媒介障害の治療における改良ナノボディ（商標）
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
WO2006129843A2 (en) * 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
CA2632866A1 (en) 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
EA200801166A1 (ru) 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
US20100047171A1 (en) * 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
MX2008012485A (es) 2006-03-30 2008-10-10 Novartis Ag Composiciones y metodos de uso para anticuerpos de c-met.
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
CA2658612C (en) * 2006-08-03 2015-11-17 Astrazeneca Ab Antibodies directed to .alpha.v.beta.6 and uses thereof
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
AU2007306340A1 (en) * 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
CA2671581A1 (en) * 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
CN101855241B (zh) 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
CA2672595A1 (en) 2006-12-15 2008-06-19 Guy Hermans Amino acid sequences that modulate the interaction between cells of the immune system
CA2672944A1 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
BRPI0812298A2 (pt) 2007-05-24 2016-05-24 Ablynx Nv sequência de aminoácidos direcionada contra rankl e polipeptídeos compreendendo a mesma para o tratamento de transtornos e doenças ósseas.
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AR062123A1 (es) 2007-07-27 2008-10-15 Inst Nac De Tecnologia Agropec Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus
EP2197491A4 (en) * 2007-09-04 2011-01-12 Univ California HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER
BRPI0817257A2 (pt) * 2007-09-24 2015-06-16 Univ Vanderbilt Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos
CA2706200A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
CA2709399C (en) 2007-12-28 2021-01-19 Genentech, Inc. Anti-hedgehog antibodies
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
NZ589036A (en) * 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
US7858729B2 (en) 2008-05-29 2010-12-28 Novomer, Inc. Methods of controlling molecular weight distribution of polymers and compositions thereof
PL2285408T3 (pl) 2008-06-05 2019-05-31 Ablynx Nv Sekwencje aminokwasowe skierowane przeciwko białkom otoczki wirusa i polipeptydy je zawierające do leczenia chorób wirusowych
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
US8372808B2 (en) 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
US10005830B2 (en) † 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2411054A2 (en) 2009-03-27 2012-02-01 Glaxo Group Limited Drug fusions and conjugates
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
US8450888B2 (en) 2009-04-20 2013-05-28 General Electric Company Integrated brushless starter/generator system
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
EP2451839B1 (en) * 2009-07-10 2020-04-22 Ablynx N.V. Method for the production of variable domains
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
EP2507262A1 (en) * 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3309176A1 (en) 2009-12-14 2018-04-18 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use
MX2012007153A (es) 2009-12-18 2012-07-03 Sanofi Sa Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos.
RU2585534C2 (ru) 2009-12-23 2016-05-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Способ снижения иммуногенности
AU2011222980B2 (en) * 2010-03-03 2016-08-11 Ablynx N.V. Biparatopic Abeta binding polypeptides
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
EP2552962B1 (en) * 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
CN102971341A (zh) 2010-04-30 2013-03-13 埃博灵克斯股份有限公司 针对异二聚体细胞因子IL-23的p19亚基的纳米抗体的氨基酸序列
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
EP2621953B1 (en) * 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR101886898B1 (ko) * 2011-01-06 2018-08-08 글락소 그룹 리미티드 Ｔｇｆ-베타 수용체 ｉｉ에 결합하는 리간드
JP6130350B2 (ja) 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． ＴＮＦαに対する単一ドメイン抗体で免疫障害を処置する方法
WO2012130314A1 (en) † 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
LT2723771T (lt) * 2011-06-23 2019-12-10 Ablynx Nv Serumo albuminą surišantys baltymai
SG10201707604SA (en) 2011-06-23 2017-11-29 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
BR112014001855A2 (pt) 2011-07-27 2017-02-21 Glaxo Group Ltd construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto
EP2987806A3 (en) 2011-08-17 2016-07-13 Glaxo Group Limited Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US8614548B2 (en) 2012-01-19 2013-12-24 Sonoco Development Incorporated Electroluminescent display and method for production
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CA2874498A1 (en) 2012-05-22 2013-11-28 Owens Corning Intellectual Capital, Llc Laminated foam product and methods for making laminated foam products
WO2014111550A1 (en) † 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
WO2015173342A1 (en) 2014-05-16 2015-11-19 Ablynx Nv Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
KR20170002645A (ko) 2014-05-16 2017-01-06 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
JP2017534617A (ja) 2014-10-21 2017-11-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患の処置
NO2768984T3 (pt) 2015-11-12 2018-06-09
US11142569B2 (en) 2015-11-13 2021-10-12 Ablynx N.V. Serum albumin-binding immunoglobulin variable domains
TW202216787A (zh) 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及／或 lag3結合劑
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
AU2016355568A1 (en) 2015-11-18 2018-06-21 Merck Sharp & Dohme Llc PD1/CTLA4 Binders
CN114605530A (zh) 2015-11-18 2022-06-10 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
WO2017129630A1 (en) 2016-01-26 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-vwf d'd3 single-domain antibodies and polypeptides comprising thereof
RU2022101604A (ru) * 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
KR102662499B1 (ko) * 2017-01-17 2024-05-02 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
TW202413408A (zh) 2017-06-02 2024-04-01 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
WO2018220234A1 (en) * 2017-06-02 2018-12-06 Merck Patent Gmbh Adamts binding immunoglobulins
WO2018220236A1 (en) * 2017-06-02 2018-12-06 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
WO2022129560A1 (en) * 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor

Also Published As

Publication number Publication date
AU2019201606A1 (en) 2019-04-04
SG10201605048XA (en) 2016-07-28
AU2020230299B2 (en) 2022-10-06
AU2024200309A1 (en) 2024-02-08
US20170275360A1 (en) 2017-09-28
US20210388061A1 (en) 2021-12-16
JP2021107426A (ja) 2021-07-29
SG194982A1 (en) 2013-12-30
CA2837998A1 (en) 2012-12-27
WO2012175741A3 (en) 2013-02-14
EP2723769A2 (en) 2014-04-30
CN108653728B (zh) 2022-11-18
DK2723769T4 (da) 2022-09-05
AU2020230299A1 (en) 2020-10-01
IL293163A (en) 2022-07-01
AU2019201606B2 (en) 2021-04-01
US20220119497A1 (en) 2022-04-21
CN104203975A (zh) 2014-12-10
SG10201707604SA (en) 2017-11-29
JP6869923B2 (ja) 2021-05-12
AU2021201506A1 (en) 2021-03-25
EP2723769B2 (en) 2022-06-15
AU2017204339B2 (en) 2019-03-28
AU2021201506B2 (en) 2023-10-19
AU2012273929B2 (en) 2017-04-27
CN108663504B (zh) 2021-06-22
KR20190041513A (ko) 2019-04-22
JP6258199B2 (ja) 2018-01-10
PL2723769T3 (pl) 2017-07-31
US20180009888A9 (en) 2018-01-11
US20230242620A1 (en) 2023-08-03
KR20180086280A (ko) 2018-07-30
US20200325221A1 (en) 2020-10-15
JP2022031790A (ja) 2022-02-22
DK2723769T3 (en) 2017-04-03
PH12017501178A1 (en) 2018-07-23
IL250396B (en) 2022-06-01
US12006352B2 (en) 2024-06-11
US20180355031A1 (en) 2018-12-13
AU2017204339A1 (en) 2017-07-13
LT2723769T (lt) 2017-04-10
CN108659120A (zh) 2018-10-16
KR102246924B1 (ko) 2021-04-30
US20210403536A1 (en) 2021-12-30
NZ617995A (en) 2016-06-24
BR122017005075A2 (pt) 2019-09-03
CN108653728A (zh) 2018-10-16
KR102430693B1 (ko) 2022-08-08
HUE031828T2 (en) 2017-08-28
US20210388062A1 (en) 2021-12-16
CA3141978A1 (en) 2012-12-27
KR20140040779A (ko) 2014-04-03
WO2012175741A2 (en) 2012-12-27
IL250396A0 (en) 2017-03-30
PL2723769T5 (pl) 2022-10-17
RU2700630C2 (ru) 2019-09-18
EP2723769B1 (en) 2017-01-11
ES2622006T5 (es) 2022-10-13
KR102025035B1 (ko) 2019-11-04
US10858418B2 (en) 2020-12-08
ZA201309295B (en) 2015-01-28
BR112013032145A8 (pt) 2018-07-03
BR112013032145B1 (pt) 2022-09-20
US20170275361A1 (en) 2017-09-28
IL229503A0 (en) 2014-01-30
KR20220114104A (ko) 2022-08-17
CA2837998C (en) 2022-03-01
JP6982400B2 (ja) 2021-12-17
JP2024050769A (ja) 2024-04-10
AU2018202782A1 (en) 2018-05-10
MX350074B (es) 2017-08-25
BR112013032145A2 (pt) 2017-12-05
IL293155A (en) 2022-07-01
RU2019128430A (ru) 2019-10-25
JP2017160230A (ja) 2017-09-14
CN108659121A (zh) 2018-10-16
KR20190107200A (ko) 2019-09-18
US20220298227A9 (en) 2022-09-22
IL229503B (en) 2022-06-01
ES2622006T3 (es) 2017-07-05
BR122018012485B1 (pt) 2022-09-20
RU2014102007A (ru) 2015-11-27
CN108663504A (zh) 2018-10-16
US11192937B2 (en) 2021-12-07
KR20240033183A (ko) 2024-03-12
KR101965462B1 (ko) 2019-04-04
AU2018202782B2 (en) 2020-07-16
BR122017005075B1 (pt) 2022-09-20
US20140199295A1 (en) 2014-07-17
CN104203975B (zh) 2018-05-11
JP2014520134A (ja) 2014-08-21
JP2018162305A (ja) 2018-10-18
IN2014CN00373A (pt) 2015-04-03
KR102240318B1 (ko) 2021-04-15
SG10201805064SA (en) 2018-07-30
NZ716279A (en) 2017-07-28
MX2018007826A (es) 2021-12-08
US11192938B2 (en) 2021-12-07
CA3142288A1 (en) 2012-12-27
KR20210047369A (ko) 2021-04-29
MX2013014614A (es) 2014-08-01
US20200216532A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
IL250396A0 (en) Techniques for predicting, detecting, and reducing A-specific protein interference in assays involving single immunoglobulin variable domains
HK1256304A1 (zh) 用於生成單克隆抗體的方法和試劑
RS55775B2 (sr) Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
HUS2000056I1 (hu) ANTI-PD-L1 ellenanyagok és alkalmazásaik
HK1200493A1 (en) Anti-b7-h4 antibodies and their uses b7-h4
HUE051068T2 (hu) Interleukin-31 monoklonális ellenanyag
EP2733982A4 (en) CELL MEASUREMENT METHOD, CELL RESOURCE SHARING METHOD, AND CORRESPONDING DEVICE
GB201115529D0 (en) Antibodies, uses and methods
GB201115280D0 (en) Antibodies, uses and methods
EP2673641A4 (en) DOUBLE-PATH, REDUCED STEP IMMUNOASSAY DEVICE AND METHOD THEREOF
EP2714079A4 (en) ENTIMMUNIZED SERUM BINDING DOMAINS AND THEIR USE TO ENHANCE SERUM DURABILITY
EP2742067A4 (en) MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
EP2593475A4 (en) ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF
PT2564202E (pt) Métodos de deteção de anticorpos
EP2322562A4 (en) MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT
IL231404A0 (en) Antibody against affinity conjugate
EP2746394A4 (en) ANTIBODY AND COMPOSITION CONTAINING THE SAME
SG11201402709WA (en) Method and device for assaying an antigen present on erythrocytes or an antibody binding to an antigen present on erythrocytes
EP2536817A4 (en) IMMUNOASSAY DEVICES FOR THE DETECTION OF ANTIBODIES AND ANTIGENES
EP2599865A4 (en) MONOCLONAL ANTI-FDP ANTIBODY, FDP MEASUREMENT REAGENT, REAGENT KIT CONTAINING SAID ANTIBODY, AND FDP MEASUREMENT METHOD THEREOF
HK1215174A1 (zh) 針對活化蛋白 的人源化單克隆抗體及其用途
EP2669296A4 (en) ANTI-IL28B ANTIBODIES AND METHOD FOR TESTING FOR IL28B THEREOF
EP2751556A4 (en) DEVICE AND METHOD FOR DETECTION AND QUANTIFICATION OF IMMUNOLOGICAL PROTEINS, PATHOGENIC AND MICROBIAL AGENTS AND CELLS